Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A study to assess the efficacy, safety and tolerability of PF-04950615 following monthly and twice monthly injection dosing for six months in subjects on a statin with high cholesterol
To evaluate the LDL-C lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in hypercholesterolemic subjects whose LDL-cholesterol is ≥80 mg/dL on...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A study to find out if a vaccine designed to protect against a disease (group B meningococcal meningitis) is safe and protects children aged from 24 months to less than 10 years
•To describe the immune response as measured by hSBA performed with 4 primary MnB test strains, 2 expressing an LP2086 subfamily A protein and 2 expressing an LP2086 subfamily B protein, measured 1 mo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Pharma GmbH
MAJ Il y a 4 ans
Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum
To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with ticilimumab
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer, S. A
MAJ Il y a 4 ans
A 102-Week, open label, multicenter trial to investigate the efficacy of macugen for the preservation of visual function in subjects with neovascular age-related macular degeneration (AMD) and to assess the benefit of treating early choroidal neovascularization (CNV)
To assess the efficacy of Macugen 0.3 mg for the preservation of vision in subjects with early CNV lesions and established CNV lesions.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Pfizer
MAJ Il y a 4 ans
B2151005 : Etude de phase 2 randomisé, évaluant l’efficacité de l’irinotecan associé au PF-05212384 ou au cétuximab, chez des patients ayant un cancer colorectal métastatique de type KRAS et NRAS sauvage. [essai suspendu] [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité du PF-05212384 à celle du cétuximab associé à de l’irinotecan, chez des patients ayant un cancer colorectal métastatique de type KRAS et NRAS sauva...
Pays
France
Organes
Côlon ou Rectum (colorectal)
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Pfizer Limited
MAJ Il y a 4 ans
A randomized double blind, placebo controlled balanced 4-way crossover study to assess the efficacy of single oral doses of PF-00592379 on erectile function, using 100mg sildenafil as a positive control
To assess the efficacy of single oral doses of PF-00592379 in improving penile erectile activity in subjects with MED.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Pfizer Pharma GmbH
MAJ Il y a 4 ans
Randomized, Double-Blind Study of the morphine-sparing efficacy and safety of Parecoxib sodium 40 mg i.v. followed by 20 mg i.v. every 12 hours in the treatment of pain following radical prostatectomy
The primary objective of this study is to demonstrate the opioid-sparing efficacy of parecoxib 40 mg i.v. given as a loading dose followed by 20 mg i.v. in the 24 hours after the end of surgery.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A six-month, open-label outpatient, parallel group trial assessing the impact of inhaled insulin (Exubera®) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on two oral anti-diabetic agents
The primary objective is to compare the efficacy between subjects who are treated with the combination of OHA’s and Exubera® compared to subjects treated with usual diabetes care, by looking at the me...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer, S. A
MAJ Il y a 4 ans
A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma
To compare the time to tumor progression (TTP) associated with SU011248 versus that associated with IFN-a for the first-line treatment of patients with metastatic renal cell carcinoma
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Pfizer Pharma GmbH
MAJ Il y a 4 ans
A multi-center, parallel group flexible dose study with a double blind, randomized, placebo controlled phase and an open-label phase to evaluate the quality of erections in men with erectile dysfunction treated with Sildenafil citrate
The study objective is to evaluate the effect that sildenafil citrate has on the hardness of erections in males with erectile dysfunction, based on subject responses to question 5 on the Event Log (ha...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
15
16
17
18
19
20
21
22
23
24
Suivant